Chirality a Hot Commodity For Fine Chemical Players.(chiral molecules, single enantiomer drugs)

Chemical Market Reporter, December, 2000 by JARVIS, LISA

Rhodia Chirex, Dow and Cambrex beef up the toolbox. SEVERAL CONTRACT manufacturing companies are stepping up their ability to serve a potentially lucrative market area: the development, manufacture and supply of novel chiral molecules. Companies such as Dow, Cambrex and Rhodia ChiRex are quickly forming alliances that will diversify their technology platforms and reinforce their ability to get their technology and products to the marketplace.

In 1999, chiral molecules accounted for about one-third of the worldwide market for final pharmaceutical actives, according to the Falls Church, Va.-based Technology Catalysts International. Single enantiomer drugs were valued at roughly $115 billion in 1999 and are projected to grow to $150 billion by 2003. ...

Premium Content Partnership | HighBeam Research provides an in-depth online archive library of reference works. HighBeam Research
 

BNET TalkbackShare your ideas and expertise on this topic

Please add your comment:

  1. You are currently: a Guest |
  2.  

Basic HTML tags that work in comments are: bold (<b></b>), italic (<i></i>), underline (<u></u>), and hyperlink (<a href></a)

advertisement
Click Here
advertisement
  • Click Here
  • Click Here
  • Click Here
advertisement
Click Here